证券代码：603229 证券简称：奥翔药业 公告编号：2024-013 浙江奥翔药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、低风险的短期理财产品 投资金额：不超过人民币 20,000 万元 履行的审议程序：浙江奥翔药业股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开了第四届董事会第二次会议、第四届监事会第二次会议， 审议通过了《关于使用闲置自有资金进行现金管理的议案》，本议案无需提交股 东大会审议。 特别风险提示：尽管公司及子公司本次使用闲置自有资金现金管理是购 买安全性高、流动性好、低风险的短期理财产品，但仍不排除受到市场波动、宏 观经济及金融政策变化带来的系统性风险。 一、本次使用闲置自有资金进行现金管理概况 （一）现金管理目的 为提高公司及子公司资金使用效率，在不影响公司及子公司正常经营的情况 下，合理利用闲置自有资金，增加资金收益，为公司及股东获取更多的投资回报。 （二）现金管理投资金额 公 ...

浙江奥翔药业股份有限公司（以下简称"公司"）聘请天健会计师事务所（特 殊普通合伙）（以下简称"天健"）作为公司 2023 年度财务报告审计机构及内部 控制审计机构。根据《国有企业、上市公司选聘会计师事务所管理办法》，公司 对天健 2023 年度审计过程中的履职情况进行评估。经评估，公司认为天健在资 质等方面合规有效，履职保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、2023 年年审会计师事务所基本情况 （一）机构信息 浙江奥翔药业股份有限公司 2023 年度会计师事务所履职情况评估报告 | 基本信息 | 项目合伙人 | 签字注册会计师 | 项目质量复核人员 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 沈维华 | 陈夏连 | 金晨希 | 何时成为注册会 | | | | | | | | | | | 1998 | 年 | 12 | 月 | 2014 | 年 | 9 | 月 | 2005 | 年 | 12 | 月 | 计师 ...

1、在公司或者其附属企业任职的人员及其配偶、父母、子女、主要社会关 系； 2、直接或者间接持有公司已发行股份 1%以上或者是公司前十名股东中的自 然人股东及其配偶、父母、子女； 3、在直接或者间接持有公司已发行股份 5%以上的股东或者在公司前五名股 东任职的人员及其配偶、父母、子女； 4、在公司控股股东、实际控制人的附属企业任职的人员及其配偶、父母、 浙江奥翔药业股份有限公司 2023 年度独立董事述职报告 作为浙江奥翔药业股份有限公司（以下简称"公司"）的独立董事，2023 年 度本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律法规 的规定及《公司章程》《独立董事工作制度》的要求，认真、忠实、勤勉地履行 工作职责，客观、独立和公正的参与公司决策，充分发挥了独立董事的作用，维 护了全体股东和公司的利益，促进公司的规范运作。现将本人 2023 年度履职情 况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人骆铭民，中国国籍，无永久境外居留权，男，1973 年出生，博士，副 教授，浙江财经大学硕士生导师、MBA 导师。1998 年 3 月至今在浙江财经大学会 计学 ...

浙江奥翔药业股份有限公司董事会 2024 年 4 月 25 日 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，浙江奥翔药业 股份有限公司（以下简称"公司"）董事会就公司在任独立董事骆铭民先生、杨 立荣先生和杨述兴先生的独立性情况进行评估并出具如下专项意见： 经核查上述人员的任职经历以及其签署的相关自查报告，上述人员未在公 司担任除独立董事及董事会各相关专门委员会委员以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，符合《上市公司独立董事管理办法》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等规定中对独立董事独 立性的相关要求。 浙江奥翔药业股份有限公司董事会 关于独立董事独立性评估的专项意见 ...

浙江奥翔药业股份有限公司 关于 2024 年度开展外汇衍生品交易的 可行性分析报告 一、业务背景 浙江奥翔药业股份有限公司（以下简称"公司"）出口业务占销售收入的比 重较高，主要采用美元等外币进行结算，因此当汇率出现较大波动时，汇兑损益 对公司的经营业绩会造成一定的影响。为降低汇率波动对公司业绩的影响，公司 及子公司拟开展外汇衍生品交易业务。 二、基本情况 （一）交易金额 公司及子公司拟使用最高额不超过 10 亿元人民币（或等值外币）开展外汇 衍生品交易业务，在上述额度及股东大会决议有效期内，可循环滚动使用，且任 一时点的交易金额不超过 10 亿元人民币（或等值外币）。 （二）资金来源 为自有资金，不涉及使用募集资金。 公司及子公司拟开展的外汇衍生品交易主要包括远期、掉期、期权、期货等 产品或上述产品的组合，对应基础资产包括汇率、利率、货币、商品或上述资产 的组合。交易对方为具有外汇衍生品交易业务经营资质的银行等金融机构。 （四）交易期限 （三）交易方式 上述额度的使用期限自公司 2023 年年度股东大会审议通过之日起一年内。 三、必要性和可行性分析 随着公司海外业务持续发展，公司涉及大量外币业务。受国际政治 ...

Financial Performance - The company's operating revenue for 2023 was CNY 816,765,083.27, representing a year-over-year increase of 6.83% compared to CNY 764,547,389.04 in 2022[22]. - The net profit attributable to shareholders of the listed company reached CNY 253,901,967.43, up 7.87% from CNY 235,375,827.46 in the previous year[22]. - The net cash flow from operating activities significantly increased by 84.00%, totaling CNY 221,847,783.71 compared to CNY 120,567,033.68 in 2022[22]. - The total assets of the company at the end of 2023 were CNY 2,951,571,189.46, reflecting a 27.48% increase from CNY 2,315,330,188.78 at the end of 2022[22]. - The basic earnings per share for 2023 was CNY 0.43, a 4.88% increase from CNY 0.41 in 2022[23]. - The weighted average return on equity decreased to 12.73%, down 4.63 percentage points from 17.36% in 2022[23]. - The company reported a net profit of CNY 93,672,808.45 in the first quarter of 2023, with a decline in the second quarter to CNY 66,523,939.88[25]. - The company's net assets attributable to shareholders increased by 46.57% to CNY 2,141,576,554.10 at the end of 2023 from CNY 1,461,140,520.64 at the end of 2022[22]. - The company achieved operating revenue of 816.77 million yuan, a year-on-year increase of 6.83%[33]. - The net profit attributable to shareholders was 253.90 million yuan, reflecting a year-on-year growth of 7.87%[33]. Research and Development - R&D investment reached 78.06 million yuan, accounting for 9.56% of operating revenue[36]. - The company has established a research and development team of 241 members, including PhDs and Masters, to enhance its R&D capabilities[36]. - The company emphasizes R&D as a key driver for growth, focusing on high-end, intelligent, and green transformation in the pharmaceutical industry[32]. - The company is leveraging partnerships with renowned universities and research institutions to boost R&D efficiency and innovation[35]. - The company has a significant focus on R&D, with a capitalized R&D ratio of 0% and a net asset ratio of 3.64%[104]. - The company plans to enhance its R&D capabilities by building a comprehensive R&D system and collaborating with renowned universities and research institutions[121]. - The company reported R&D expenditures of 78.06 million RMB, accounting for 9.56% of operating revenue[104]. - The company has multiple drug products under review, including 3 products for pulmonary arterial hypertension and 5 for ophthalmic use, with various approval statuses across regions[100]. Market and Industry Trends - The global pharmaceutical market is projected to grow from approximately $1.48 trillion in 2022 to $1.9 trillion by 2027, with a CAGR of 3-6%[39]. - The aging population in China is a significant driver for the pharmaceutical market, with the population aged 65 and above increasing from 140 million in 2014 to 220 million in 2023[40]. - The global pharmaceutical expenditure was approximately $1.48 trillion in 2022, with a projected CAGR of 3-6%, reaching $1.9 trillion by 2027[87]. - China's pharmaceutical market size was ¥1,554.1 billion in 2022, expected to reach ¥2,624.5 billion by 2030, with the chemical drug segment accounting for 50% of the total market[43]. - The company has identified a trend of increasing demand for pharmaceutical formulations due to global aging and rising healthcare awareness[117]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[4]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the annual report's authenticity[9]. - The company emphasizes the importance of independent governance and compliance with legal regulations in its operations and decision-making processes[128]. - The company has a clear governance structure with no significant differences from regulatory requirements[130]. - The company is focused on maintaining independence from its controlling shareholders and has not reported any related issues[130]. - The company has not faced any delisting risks during the reporting period[188]. - The company has not reported any significant changes in its integrity status or that of its major stakeholders[189]. Environmental Responsibility - The company invested RMB 23.426 million in environmental protection during the reporting period[171]. - Aoxiang Pharmaceutical is listed as a key pollutant discharge unit by the environmental protection department for 2023[172]. - The total non-methane hydrocarbon emissions for 2023 were 1.82 tons, with an average emission concentration of 16.92 mg/m³[172]. - The wastewater discharge for 2023 was 168,342.76 tons, with a total allowable discharge of 268,780 tons, and an average chemical oxygen demand concentration of 218.8 mg/L[172]. - Aoxiang Pharmaceutical has established a complete environmental risk emergency mechanism, with an emergency plan filed on November 15, 2023[176]. - The company has no administrative penalties for environmental issues during the reporting period[178]. - Aoxiang Pharmaceutical has implemented a self-monitoring plan for environmental pollutants, with all monitored indicators meeting discharge standards[177]. Shareholder and Capital Management - The company plans to distribute a cash dividend of RMB 1.29 per 10 shares, totaling RMB 76,505,951.18, and to increase its share capital by 237,227,756 shares through a capital reserve transfer, raising total shares from 593,069,389 to 830,297,145[5]. - The company reported a significant increase in shareholding for Chairman and General Manager Zheng Zhiguo, from 214,506,991 shares at the beginning of the year to 300,309,788 shares, an increase of 40%[133]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 7.5806 million yuan[144]. - The company has a structured process for determining the remuneration of its board members, ensuring alignment with performance metrics[144]. - The company has proposed to change its corporate type and has submitted relevant resolutions for approval[149]. Operational Efficiency and Cost Management - The company is enhancing its production management and cost control measures to improve operational efficiency[36]. - The management team is committed to enhancing operational efficiency and cost management to improve overall financial performance[136]. - The company is focusing on developing a one-stop service model by vertically integrating CRO/CDMO/CMO services across all stages of the pharmaceutical development process[48]. - The company is investing in advanced technologies to enhance drug development processes, including enzyme catalysis and continuous flow reaction technologies, to optimize production efficiency and reduce costs[49]. Risk Management - The company has outlined potential risks in the management discussion and analysis section, advising investors to be cautious[10]. - The company faces risks related to product quality, requiring compliance with GMP and cGMP certifications for domestic and export sales[123]. - Environmental risks are heightened due to complex chemical processes that generate waste, necessitating increased investment in environmental compliance[124]. - The company is exposed to exchange rate fluctuations due to a significant portion of revenue being generated from exports settled in foreign currencies[125].

浙江奥翔药业股份有限公司 2023 年度独立董事述职报告 作为浙江奥翔药业股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律法规的规定及 《公司章程》《独立董事工作制度》的要求，认真、忠实、勤勉地履行工作职责， 客观、独立和公正的参与公司决策，充分发挥了独立董事的作用，维护了全体股 东和公司的利益，促进公司的规范运作。现将本人 2023 年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人杨述兴，中国国籍，无永久境外居留权，男，1973 年出生，博士，副 教授，硕士生导师。现为中国农业大学人文与发展学院法律系主任。兼任中国农 业农村法治研究会常务理事、副秘书长；中国法学会法学教育研究会理事；中国 法学会知识产权法学研究会理事。现任浙江奥翔药业股份有限公司独立董事。 （二）独立性的情况说明 本人具备独立性，不属于下列情形： 1、在公司或者其附属企业任职的人员及其配偶、父母、子女、主要社会关 系； 2、直接或者间接持有公司已发行股份 1%以上或者是公司前十名股东中的自 然人股东及其配偶、父母、子女； 3、在直接 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 300,914,417.10, representing a year-on-year increase of 14.61%[4] - The net profit attributable to shareholders for the same period was CNY 112,480,834.45, reflecting a growth of 20.08% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 108,489,854.53, which is an increase of 17.69% year-on-year[4] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.19, marking an increase of 18.75%[4] - Total operating revenue for Q1 2024 reached ¥300,914,417.10, a 14.6% increase from ¥262,549,690.48 in Q1 2023[17] - Net profit attributable to shareholders for Q1 2024 was ¥112,480,834.45, representing a 20% increase compared to ¥93,672,808.45 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both ¥0.19, up from ¥0.16 in Q1 2023[18] Cash Flow - The net cash flow from operating activities decreased by 39.98%, primarily due to a relative reduction in received payments compared to the same period last year[7] - Cash flow from operating activities in Q1 2024 was ¥166,699,040.56, down from ¥208,507,860.64 in Q1 2023, indicating a decrease of 20.1%[19] - The net cash flow from operating activities for Q1 2024 was ¥26,983,529.17, a decrease of 40% compared to ¥44,955,913.77 in Q1 2023[20] - The total cash inflow from financing activities was ¥70,000,000.00, significantly lower than ¥573,933,781.92 in the previous year[21] - The net cash flow from investing activities was -¥21,275,021.86, compared to -¥81,121,541.50 in Q1 2023, indicating a reduced outflow[20] - The total cash outflow for operating activities was ¥179,967,435.29, compared to ¥243,010,208.91 in the previous year, showing a decrease in cash expenses[20] - The company experienced a negative impact of -¥691,997.96 from exchange rate fluctuations on cash and cash equivalents[21] - The net increase in cash and cash equivalents for Q1 2024 was -¥14,742,889.83, contrasting sharply with an increase of ¥501,884,558.67 in Q1 2023[21] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 3,045,057,290.07, up 3.17% from the end of the previous year[5] - The company's current assets totaled RMB 1,762,690,515.89, up from RMB 1,674,726,430.55, indicating an increase of about 5.2%[12] - Accounts receivable rose significantly to RMB 291,549,334.69 from RMB 132,750,843.88, representing an increase of approximately 119.9%[12] - Inventory decreased to RMB 311,211,637.19 from RMB 365,179,023.26, showing a decline of about 14.8%[12] - The company's total liabilities were not explicitly stated, but current liabilities included short-term borrowings of RMB 300,361,549.62, which remained relatively stable compared to RMB 300,259,888.90[13] - Total liabilities as of Q1 2024 amounted to ¥781,236,851.23, a decrease from ¥809,994,635.36 in the previous year[14] - The company’s non-current assets totaled RMB 1,282,366,774.18, a slight increase from RMB 1,276,844,758.91, reflecting a growth of about 0.4%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,488[9] - There were no significant changes reported in the top 10 shareholders or their shareholdings during the reporting period[10] Expenses and Other Financial Metrics - Operating costs for Q1 2024 were ¥167,168,222.81, up 10.9% from ¥150,656,558.62 in Q1 2023[17] - Research and development expenses for Q1 2024 were ¥23,250,646.98, an increase of 8.3% from ¥21,462,162.83 in Q1 2023[17] - The company reported a credit impairment loss of ¥7,737,852.29 in Q1 2024, compared to ¥2,691,497.15 in Q1 2023, indicating a significant increase in credit risk[17] - Deferred income tax liabilities rose to ¥2,659,507.82 in Q1 2024 from ¥2,073,627.22 in Q1 2023, showing an increase of 28.2%[14] - The company paid ¥62,363,523.90 in employee compensation, which is an increase from ¥59,126,401.00 in Q1 2023[20]

本人杨立荣，中国国籍，无永久境外居留权，男，1962 年出生，博士，教 授，博士生导师。曾任教于浙江工业大学，并曾担任浙江九洲药业股份有限公司 独立董事、浙江奥锐特药业股份有限公司独立董事等。现为浙江大学化学工程与 生物工程学院教授、浙江大学杭州国际科创中心生物与分子智造研究院首席科学 家。现任浙江奥翔药业股份有限公司独立董事，同时担任浙江海正药业股份有限 公司独立董事等。 （二）独立性的情况说明 浙江奥翔药业股份有限公司 2023 年度独立董事述职报告 作为浙江奥翔药业股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律法规的规定及 《公司章程》《独立董事工作制度》的要求，认真、忠实、勤勉地履行工作职责， 客观、独立和公正的参与公司决策，充分发挥了独立董事的作用，维护了全体股 东和公司的利益，促进公司的规范运作。现将本人 2023 年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人具备独立性，不属于下列情形： 1、在公司或者其附属企业任职的人员及其配偶、父母、子女、主要社会关 系； 2、直接或者间接持有公 ...

| 单位：万元 | | --- | 证券代码：603229 证券简称：奥翔药业 公告编号：2024-008 浙江奥翔药业股份有限公司 关于 2024 年度向金融机构申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江奥翔药业股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 了第四届董事会第二次会议，审议通过了《关于 2024 年度向金融机构申请综合 授信额度的议案》，现将具体情况公告如下： 根据公司 2024 年度经营计划及资金预算，公司及子公司拟向银行等金融机 构申请总额不超过人民币 385,000.00 万元综合授信额度。明细如下： 公司董事会提请股东大会授权公司董事长及其授权人士在上述授信额度内 全权代表公司办理相关业务，并签署有关法律文件。 以上议案尚需提交公司 2023 年年度股东大会审议，所称额度有效期为 2023 年年度股东大会审议通过本议案之日起至 2024 年年度股东大会召开之日。 特此公告。 浙江奥翔药业股份有限公司董事会 2024 年 4 月 27 日 | 序 ...